Evidence for a multivalent effect in inhibition of sulfatases involved in lysosomal storage disorders (LSDs)
Authors: D’Adamio G., Matassini C., Parmeggiani C., Catarzi S., Morrone A., Goti A., Paoli P., Cardona F.
Autors Affiliation: Univ Florence, Dept Chem Ugo Schiff, Via Lastruccia 3-13, I-50019 Sesto Fiorentino, FI, Italy; CNR, INO, Via N Carrara 1, I-50019 Sesto Fiorentino, FI, Italy; LENS, Via N Carrara 1, I-50019 Sesto Fiorentino, FI, Italy; Univ Florence, Dept Neurosci Pharmacol & Child Hlth, Meyer Childrens Hosp, Paediat Neurol Unit & Labs,Neurosci Dept, Viale Pieraccini 24, I-50139 Florence, Italy; Univ Florence, Dept Expt & Clin Biomed Sci, Viale Morgagni 50, I-50134 Florence, Italy
Abstract: Two newly synthesized nonavalent polyhydroxylated pyrrolidine iminosugars are the first examples of multivalent inhibitors of GALNS and IDS lysosomal enzymes, whose deficiency leads to Morquio A syndrome and Hunter disease, respectively, and pave the way to a pharmacological chaperone or stabilizing enzyme therapy for these LSDs.
Journal/Review: RSC ADVANCES
Volume: 6 (69) Pages from: 64847 to: 64851
KeyWords: ENZYME REPLACEMENT THERAPY; IMINOSUGAR CLICK CLUSTERS; PHARMACOLOGICAL CHAPERONES; GAUCHER-DISEASE; HYACINTHACINE A(2); DIAGNOSIS; MORQUIO; GLUCOCEREBROSIDASE; 7-DEOXYCASUARINE; ARCHITECTURESDOI: 10.1039/c6ra15806dCitations: 10data from “WEB OF SCIENCE” (of Thomson Reuters) are update at: 2021-10-17References taken from IsiWeb of Knowledge: (subscribers only)Connecting to view paper tab on IsiWeb: Click hereConnecting to view citations from IsiWeb: Click here